A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis
Authors:
- Mikio SugimotoMSMikio Sugimoto
- Xia ZhangXZXia Zhang
- Nobufumi UedaNUNobufumi Ueda
- Hiroyuki TsunemoriHTHiroyuki Tsunemori
- Rikiya TaokaRTRikiya Taoka
- Yusi HayashidaYHYusi Hayashida
- Hiromi HiramaHHHiromi Hirama
- Yasuyuki MiyauchiYMYasuyuki Miyauchi
- Yuki MatsuokaYMYuki Matsuoka
- Hirohito NaitoHNHirohito Naito
- Yu OsakiYOYu Osaki
Open Access
- 23 October 2019
- journal article
- research article
- Published by Springer Nature in BMC Urology
- Vol. 19 (1) , 1-7
Abstract
Background: Chronic inflammation is thought to be a major causative factor for the development of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Tadalafil, a phosphodiesterase type 5 inhibitor (PDE5-I), which has been used for the treatment of BPH-LUTS in daily practice, is known to act at several urinary organs. In this study, focused on the prostate, we examined the effect of tadalafil on the pathological changes and inflammatory factors in a rat nonbacterial prostatitis (NBP) model. Methods: Forty ten-month-old male Wistar rats were divided into nonbacterial prostatitis (NBP), NBP with tadalafil treatment (NBP-tadalafil), control, and control treated with tadalafil (control-tadalafil) groups (n = 10 per group). The NBP and NBP-tadalafil groups were castrated and then received daily subcutaneous 17β-estradiol for 30 days. The control-tadalafil and NBP-tadalafil groups were administered daily oral tadalafil for 30 days. All rats were then sacrificed and pathological changes and inflammatory factors were assessed in the prostatic tissues. Results: In the NBP group, the stroma-to-epithelium (S/E) ratio in the ventral prostate was significantly higher than in the control group (P < 0.001). In the NBP-tadalafil group, the S/E ratio was significantly lower than in the NBP group (P < 0.001). The macrophage levels and the extent of T-cell infiltration in the NBP-tadalafil group were significantly lower than in the NBP group (P < 0.005; P < 0.001, respectively). Compared with the NBP group, tissue concentrations of inflammatory cytokines, such as tumor necrosis factor-α, interleukin-8, and interleukin-1β, were significantly downregulated in the NBP-tadalafil group (P < 0.01; P < 0.05; P < 0.005, respectively). Conclusions: Tadalafil suppressed stromal predominance and showed anti-inflammatory effects in a rat NBP model in association with downregulation of inflammatory cytokines.Keywords
This publication has 26 references indexed in Scilit:
- EAU Guidelines on the Treatment and Follow-up of Non-neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic ObstructionEuropean Urology, 2013
- Tadalafil: A Phosphodiesterase‐5 Inhibitor for Benign Prostatic HyperplasiaPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2013
- Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome‐associated prostate alterations: An experimental study in the rabbitThe Prostate, 2012
- Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunctionBritish Journal of Clinical Pharmacology, 2011
- Effect of a phytotherapeutic agent, Eviprostat®, on prostatic and urinary cytokines/chemokines in a rat model of nonbacterial prostatitisThe Prostate, 2010
- Evaluation of Interleukin-8 in Expressed Prostatic Secretion as a Reliable Biomarker of Inflammation in Benign Prostatic HyperplasiaUrology, 2009
- The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) studyBJU International, 2009
- Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC StudyEuropean Urology, 2006
- Lower urinary tract symptoms and male sexual dysfunction in Asia: a survey of ageing men from five Asian countriesBJU International, 2005
- IL-1β AND TNF-α IN PROSTATIC SECRETIONS ARE INDICATORS IN THE EVALUATION OF MEN WITH CHRONIC PROSTATITISJournal of Urology, 2000